Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)

Recruiting

Phase N/A Results N/A

Trial Description

Describe patient and physician assessed factors for patient well-being when treated with Pradaxa for stroke and embolism prevention in atrial fibrillation either compared to previous antithrombotic treatment (switcher)

Conditions

Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Non-Probability Sample

Trial Population

spanish patients with a diagnosis of non-valvular atrial fibrillation

Outcomes

Type Measure Time Frame Safety Issue
Primary Mean of Perception of Anticoagulant Treatment Questionnaire (PACT-Q2) scores at second and last assessment compared to baseline assessment 6 months No
Primary Mean of Perception of Anticoagulant Treatment Questionnaire (PACT-Q2) score at last assessment compared to second assessment 6 months No
Secondary Dosing of Pradaxa At baseline, visit 1 month, visit 6 months No
Secondary Gender (male/famale) At baseline, visit 1 month, visit 6 months No
Secondary Score for atrial fibrillation stroke risk (CHA2-DS2-VASc score) At baseline, visit 1 month, visit 6 months No
Secondary Kidney function: creatinine clearance At baseline, visit 1 month, visit 6 months No
Secondary Duration of previous vitamin K antagonist (VKA) treatment At baseline, visit 1 month, visit 6 months No
Secondary Age (years) At baseline, visit 1 month, visit 6 months No
Secondary Score for Major Bleeding risk (HAS-BLED score) At baseline, visit 1 month, visit 6 months No
Secondary Description of participants with concomitant diseases At baseline, visit 1 month, visit 6 months No
Secondary Description of participants with concomitant therapies At baseline, visit 1 month, visit 6 months No
Secondary Gender (male/female) At baseline, visit 1 month, visit 6 months

Sponsors